

Giovanni Guaraldi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5135853/publications.pdf>

Version: 2024-02-01

351
papers

11,896
citations

38742

50
h-index

42399

92
g-index

356
all docs

356
docs citations

356
times ranked

15945
citing authors

#	ARTICLE	IF	CITATIONS
1	Resilience and Frailty in People Living With HIV During the COVID Era: Two Complementary Constructs Associated With Health-Related Quality of Life. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2022, 89, S65-S72.	2.1	6
2	Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac003.	0.9	18
3	Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy. <i>Journal of Clinical Medicine</i> , 2022, 11, 471.	2.4	0
4	Minimal prevalence of HPV vaccination and common occurrence of high-risk HPV types in pregnant women with HIV: data from a national study in Italy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 505-509.	2.9	0
5	Metabolic reprogramming shapes neutrophil functions in severe COVID-19. <i>European Journal of Immunology</i> , 2022, 52, 484-502.	2.9	34
6	Two-Tier Care Pathways for Liver Fibrosis Associated to Non-Alcoholic Fatty Liver Disease in HIV Mono-Infected Patients. <i>Journal of Personalized Medicine</i> , 2022, 12, 282.	2.5	1
7	“Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV”, <i>HIV Medicine</i> , 2022, 23, 911-921.	2.2	3
8	Awaiting a cure for COVID-19: therapeutic approach in patients with different severity levels of COVID-19. <i>Infezioni in Medicina</i> , 2022, 30, 11-21.	1.1	3
9	Plasma Cytokine Atlas Reveals the Importance of TH2 Polarization and Interferons in Predicting COVID-19 Severity and Survival. <i>Frontiers in Immunology</i> , 2022, 13, 842150.	4.8	15
10	Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021. <i>HIV Medicine</i> , 2022, 23, 849-858.	2.2	57
11	The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. <i>HIV Medicine</i> , 2022, 23, 585-598.	2.2	2
12	HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. <i>HIV Medicine</i> , 2022, 23, 684-692.	2.2	4
13	Primary, secondary and compensated male biochemical hypogonadism in people living with HIV (PLWH): relevance of sex hormone-binding globulin (SHBG) measurement and comparison between liquid chromatography-tandem mass spectrometry (LC-MS/MS) and chemiluminescent immunoassay for sex steroids assay. <i>Ageing Male</i> , 2022, 25, 41-53.	1.9	8
14	Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	3.0	1
15	Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality. <i>Intensive Care Medicine</i> , 2022, 48, 706-713.	8.2	39
16	Molecular and cellular immune features of aged patients with severe COVID-19 pneumonia. <i>Communications Biology</i> , 2022, 5, .	4.4	27
17	The interplay of post-acute COVID-19 syndrome and aging: a biological, clinical and public health approach. <i>Ageing Research Reviews</i> , 2022, 81, 101686.	10.9	6
18	Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Mono-infection. <i>Clinical Infectious Diseases</i> , 2021, 73, e2184-e2193.	5.8	14

#	ARTICLE	IF	CITATIONS
19	Two fatal cases of acute liver failure due to HSV-1 infection in COVID-19 patients following immunomodulatory therapies. <i>Clinical Infectious Diseases</i> , 2021, 73, e252-e255.	5.8	39
20	Human Immunodeficiency Virus (HIV) Care Models During the Coronavirus Disease 2019 (COVID-19) Era. <i>Clinical Infectious Diseases</i> , 2021, 73, e1222-e1227.	5.8	30
21	Efficient T-Cell Compartment in HIV-Positive Patients Receiving Orthotopic Liver Transplant and Immunosuppressive Therapy. <i>Journal of Infectious Diseases</i> , 2021, 223, 482-493.	4.0	0
22	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1054-1065.	3.4	87
23	Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021, 16, e0247275.	2.5	7
24	Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV. <i>Aids</i> , 2021, 35, 939-945.	2.2	19
25	CD4/CD8 ratio in pregnant women with HIV and its association with pregnancy outcome: data from a national study in Italy. <i>Infection</i> , 2021, 49, 955-964.	4.7	0
26	Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features. <i>Nature Communications</i> , 2021, 12, 2593.	12.8	94
27	The impact of chest CT body composition parameters on clinical outcomes in COVID-19 patients. <i>PLoS ONE</i> , 2021, 16, e0251768.	2.5	26
28	Twenty-four-hour serum creatinine variation is associated with poor outcome in the novel coronavirus disease 2019 (COVID-19) patients. <i>Kidney Research and Clinical Practice</i> , 2021, 40, 231-240.	2.2	14
29	Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. <i>Frontiers in Medicine</i> , 2021, 8, 639970.	2.6	20
30	Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2380-2393.	3.0	13
31	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-10.	1.9	2
32	Persistent SARS-CoV-2 positivity. <i>Infectious Diseases in Clinical Practice</i> , 2021, 29, e328-e329.	0.3	7
33	The Impact of COVID-19 on UNAIDS 90-90-90 Targets: Calls for New HIV Care Models. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab283.	0.9	13
34	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. <i>Nature Communications</i> , 2021, 12, 4450.	12.8	67
35	Endogenous control of inflammation characterizes pregnant women with asymptomatic or paucisymptomatic SARS-CoV-2 infection. <i>Nature Communications</i> , 2021, 12, 4677.	12.8	29
36	Incidence, risk factors and outcome of acute kidney injury (AKI) in patients with COVID-19. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 1203-1214.	1.6	27

#	ARTICLE	IF	CITATIONS
37	Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy. <i>ELife</i> , 2021, 10, .	6.0	10
38	Herpes Simplex Virus Re-Activation in Patients with SARS-CoV-2 Pneumonia: A Prospective, Observational Study. <i>Microorganisms</i> , 2021, 9, 1896.	3.6	28
39	Sarcopenic obesity at the crossroad of pathogenesis of cardiometabolic diseases. <i>Atherosclerosis</i> , 2021, 335, 84-86.	0.8	3
40	Liver Transplantation for HCC in HIV-Infected Patients: Long-Term Single-Center Experience. <i>Cancers</i> , 2021, 13, 4727.	3.7	6
41	Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. <i>Lancet HIV</i> , 2021, 8, e711-e722.	4.7	35
42	Health status is related to testosterone, estrone and body fat: moving to functional hypogonadism in adult men with HIV. <i>European Journal of Endocrinology</i> , 2021, 184, 107-122.	3.7	17
43	Durability of Integrase STRand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPO cohort. <i>PLoS ONE</i> , 2021, 16, e0258533.	2.5	0
44	Methylprednisolone as rescue therapy after tocilizumab failure in patients with severe COVID-19 pneumonia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1141.	0.8	0
45	Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV monoinfected patients. <i>HIV Medicine</i> , 2020, 21, 96-108.	2.2	12
46	The EuroSIDA study: 25 years of scientific achievements. <i>HIV Medicine</i> , 2020, 21, 71-83.	2.2	24
47	Vitamin E as a "bridge"™ therapy for nonalcoholic steatohepatitis in HIV: what is waiting on the other side of the bridge?. <i>Aids</i> , 2020, 34, 317-319.	2.2	1
48	Pregnancy and neonatal outcomes in women with HIV-1 exposed to integrase inhibitors, protease inhibitors and non-nucleoside reverse transcriptase inhibitors: an observational study. <i>Infection</i> , 2020, 48, 249-258.	4.7	11
49	Tocilizumab in COVID-19: finding the optimal route and dose " Authors' reply. <i>Lancet Rheumatology</i> , 2020, 2, e739-e740.	3.9	3
50	A patient-centred approach to deprescribing antiretroviral therapy in people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3425-3432.	3.0	9
51	Epidemiology and Risk Factors Associated With Mortality in Consecutive Patients With Bacterial Bloodstream Infection: Impact of MDR and XDR Bacteria. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa461.	0.9	41
52	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1899-1913.	2.6	137
53	Long-term effects of COVID 19 in a patient on maintenance dialysis. <i>Hemodialysis International</i> , 2020, 24, E50-E54.	0.9	9
54	Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3334-3343.	3.0	5

#	ARTICLE	IF	CITATIONS
55	Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID-19 patients with pneumonia. <i>European Journal of Immunology</i> , 2020, 50, 1283-1294.	2.9	95
56	P1668SIMULTANEOUS LIVER-KIDNEY TRANSPLANTATION IN PEOPLE LIVING WITH HIV: A CASE-SERIES WITH LONG TERM FOLLOW-UP. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
57	Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV. <i>Aids</i> , 2020, 34, 1915-1921.	2.2	11
58	Surfactant replacement might help recovery of low-compliance lung in severe COVID-19 pneumonia. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662095104.	2.6	33
59	2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. <i>HIV Medicine</i> , 2020, 21, 617-624.	2.2	115
60	Tocilizumab for severe COVID-19 pneumonia – Authors' reply. <i>Lancet Rheumatology</i> , The, 2020, 2, e660-e661.	3.9	39
61	Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV. <i>HIV Research and Clinical Practice</i> , 2020, 21, 91-98.	1.1	8
62	Tocilizumab in patients with severe COVID-19: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e474-e484.	3.9	772
63	SARS-CoV-2, the Virus that Causes COVID-19: Cytometry and the New Challenge for Global Health. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 340-343.	1.5	91
64	Successful treatment of BK virus associated-nephropathy in a human immunodeficiency virus-positive kidney transplant recipient. <i>International Journal of STD and AIDS</i> , 2020, 31, 387-391.	1.1	2
65	Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. <i>Nature Communications</i> , 2020, 11, 3434.	12.8	636
66	Sex Differences in People Aging With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 284-291.	2.1	22
67	Prevalence, Correlates and Outcomes of Smoking in Pregnant Women with HIV: A National Observational Study in Italy. <i>Substance Use and Misuse</i> , 2020, 55, 1165-1172.	1.4	4
68	18Fluoride-based molecular imaging of coronary atherosclerosis in HIV infected patients. <i>Atherosclerosis</i> , 2020, 297, 127-135.	0.8	14
69	New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. <i>Hepatology</i> , 2020, 71, 1831-1844.	7.3	16
70	Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 2020, 222, 787-797.	4.0	12
71	Handling and Processing of Blood Specimens from Patients with COVID-19 for Safe Studies on Cell Phenotype and Cytokine Storm. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 668-673.	1.5	26
72	Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 71, e694-e701.	5.8	27

#	ARTICLE	IF	CITATIONS
73	The Lisbon patient: exceptional longevity with HIV suggests healthy aging as an ultimate goal for HIV care. <i>BMC Infectious Diseases</i> , 2020, 20, 290.	2.9	1
74	Role of Maraviroc in minimizing the risk of graft rejection in HIV-infected kidney transplant recipients. <i>Transplant Infectious Disease</i> , 2020, 22, e13294.	1.7	1
75	Weight Gain during Pregnancy in Women with HIV Receiving Different Antiretroviral Regimens. <i>Antiviral Therapy</i> , 2020, 25, 315-325.	1.0	4
76	Machine learning in predicting respiratory failure in patients with COVID-19 pneumonia—Challenges, strengths, and opportunities in a global health emergency. <i>PLoS ONE</i> , 2020, 15, e0239172.	2.5	43
77	Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia. <i>EMBO Molecular Medicine</i> , 2020, 12, e13001.	6.9	133
78	OUP accepted manuscript. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 265-268.	2.9	16
79	Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa470.	0.9	1
80	Title is missing!. , 2020, 15, e0239172.		0
81	Title is missing!. , 2020, 15, e0239172.		0
82	Title is missing!. , 2020, 15, e0239172.		0
83	Title is missing!. , 2020, 15, e0239172.		0
84	RELATIONSHIP BETWEEN GRIP STRENGTH AND NONALCOHOLIC FATTY LIVER DISEASE IN MEN LIVING WITH HIV REFERRED TO A METABOLIC CLINIC. <i>Journal of Frailty & Aging</i> , 2019, 8, 1-4.	1.3	7
85	Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 597-606.	5.8	34
86	Antiviral activity of sirolimus in an HIV-positive kidney transplant recipient. <i>International Journal of STD and AIDS</i> , 2019, 30, 919-922.	1.1	7
87	Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian GEPPO Cohort. <i>PLoS ONE</i> , 2019, 14, e0222225.	2.5	9
88	Significant chronic airway abnormalities in never-smoking HIV-infected patients. <i>HIV Medicine</i> , 2019, 20, 657-667.	2.2	14
89	Thymus Imaging Detection and Size Is Inversely Associated With Metabolic Syndrome and Frailty in People With HIV. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz435.	0.9	5
90	The Interplay Between Frailty and Intrinsic Capacity in Aging and HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 1013-1022.	1.1	14

#	ARTICLE	IF	CITATIONS
91	Compression of frailty in adults living with HIV. <i>BMC Geriatrics</i> , 2019, 19, 229.	2.7	5
92	Why Am I Getting Fat? Exploring Immune-Metabolic Pathways to Central Fat Accumulation in Persons With HIV. <i>Journal of Infectious Diseases</i> , 2019, 221, 343-345.	4.0	3
93	Progressive increases in fat mass occur in adults living with HIV on antiretroviral therapy, but patterns differ by sex and anatomic depot. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1028-1034.	3.0	37
94	Older HIV-infected adults: complex patients' geriatric syndromes (II). <i>European Geriatric Medicine</i> , 2019, 10, 213-218.	2.8	2
95	A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice. <i>AIDS Reviews</i> , 2019, 20, 75-82.	1.0	2
96	The Interplay Between Age and Frailty in People Living With HIV: Results From an 11-Year Follow-up Observational Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz199.	0.9	8
97	Impact of prolonged maraviroc treatment on non-AIDS-related comorbidities in HIV-positive patients: a retrospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2723-2731.	3.0	8
98	Lean Mass Declines Consistently over 10 Years in People living with HIV on Antiretroviral Therapy, with Patterns Differing by Sex. <i>Antiviral Therapy</i> , 2019, 24, 383-387.	1.0	11
99	AGE OF HIV ACQUISITION AFFECTS THE RISK OF MULTI-MORBIDITY AFTER 25 YEARS OF INFECTION EXPOSURE. <i>Journal of Frailty & Aging</i> , 2019, 8, 1-5.	1.3	7
100	Molecular Imaging of Vascular Calcification with ¹⁸ F-Sodium-Fluoride in Patients Infected with Human Immunodeficiency Virus. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1183.	4.1	4
101	HIV and aging: time to bridge the gap between clinical research and clinical care. <i>European Geriatric Medicine</i> , 2019, 10, 165-167.	2.8	4
102	Reliability of calcium-phosphorus (Ca/P) ratio as a new, accurate and inexpensive tool in the diagnosis of some Ca-P disorders. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 1041-1049.	3.3	15
103	What is the measure of success in HIV? The fourth 90: quality of life or healthy aging?. <i>European Geriatric Medicine</i> , 2019, 10, 267-274.	2.8	16
104	The dynamic association between Frailty, CD4 and CD4/CD8 ratio in people aging with HIV. <i>PLoS ONE</i> , 2019, 14, e0212283.	2.5	24
105	European cohorts of older HIV adults: POPPY, AGEHIV, GEPPPO, COBRA and FUNCFRIL. <i>European Geriatric Medicine</i> , 2019, 10, 247-257.	2.8	14
106	Aging with HIV. <i>Current HIV/AIDS Reports</i> , 2019, 16, 475-481.	3.1	63
107	Geriatric Syndromes in People Living with HIV Associated with Ageing and Increasing Comorbidities: Implications for Neurocognitive Complications of HIV Infection. <i>Current Topics in Behavioral Neurosciences</i> , 2019, 50, 301-327.	1.7	5
108	Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. <i>HIV Medicine</i> , 2019, 20, 99-109.	2.2	19

#	ARTICLE	IF	CITATIONS
109	Abacavir, nevirapine, and ritonavir modulate intracellular calcium levels without affecting GHRH-mediated growth hormone secretion in somatotrophic cells in vitro. <i>Molecular and Cellular Endocrinology</i> , 2019, 482, 37-44.	3.2	5
110	Management of human immunodeficiency virus in older people. <i>Australian Journal of General Practice</i> , 2019, 48, 440-445.	0.8	5
111	Highlights of the 2017 European <sc>AIDS</sc> Clinical Society (EACS) Guidelines for the treatment of adult <sc>HIV</sc>-positive persons version 9.0. <i>HIV Medicine</i> , 2018, 19, 309-315.	2.2	77
112	The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 years. <i>BMC Geriatrics</i> , 2018, 18, 99.	2.7	117
113	Brief Report: Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women With HIV: Laboratory and Clinical Outcomes in an Observational National Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 99-104.	2.1	3
114	Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1025-1030.	3.0	3
115	Role of tenofovir alafenamide in the jungle of antiretroviral prescription. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 261-262.	3.0	1
116	Bone Mineral Density Declines Twice as Quickly Among HIV-Infected Women Compared With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 288-294.	2.1	31
117	THE MANAGEMENT OF GERIATRIC AND FRAIL HIV PATIENTS. A 2017 UPDATE FROM THE ITALIAN GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS AND THE DIAGNOSTIC-CLINICAL MANAGEMENT OF HIV-1 INFECTED PERSONS. <i>Journal of Frailty & Aging</i> , 2018, 8, 1-7.	1.3	9
118	Managing antiretroviral therapy in the elderly HIV patient. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1171-1181.	3.1	9
119	Incidence of HCV infection amongst HIV positive men who had sex with men and prevalence data from patients followed at the Infectious Diseases Clinic of Modena, Italy. <i>Digestive and Liver Disease</i> , 2018, 50, 1334-1338.	0.9	3
120	Construct validation of a Frailty Index, an HIV Index and a Protective Index from a clinical HIV database. <i>PLoS ONE</i> , 2018, 13, e0201394.	2.5	10
121	Pre-exposure Prophylaxis for HIV Infection in the Older Patient: What can be Recommended?. <i>Drugs and Aging</i> , 2018, 35, 485-491.	2.7	16
122	The -COMorBidity in Relation to AIDS-™ (COBRA) cohort: Design, methods and participant characteristics. <i>PLoS ONE</i> , 2018, 13, e0191791.	2.5	12
123	HBV coinfection is associated with reduced CD4 response to antiretroviral treatment in pregnancy. <i>HIV Clinical Trials</i> , 2017, 18, 54-59.	2.0	7
124	Growth hormone deficiency and human immunodeficiency virus. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 91-111.	4.7	27
125	Clinical implications of aging with HIV infection. <i>Aids</i> , 2017, 31, S129-S135.	2.2	72
126	Metabolic concerns in aging HIV-infected persons. <i>Aids</i> , 2017, 31, S147-S156.	2.2	37

#	ARTICLE	IF	CITATIONS
127	Cardiovascular Risk Prediction in Patients With Human Immunodeficiency Virus. <i>JAMA Cardiology</i> , 2017, 2, 1048.	6.1	3
128	Geriatric-HIV medicine: A science in its infancy. <i>Virulence</i> , 2017, 8, 504-507.	4.4	8
129	Antiretroviral therapies and cardiovascular risk: True or false?. <i>Atherosclerosis</i> , 2017, 263, 313-314.	0.8	3
130	Antiretroviral therapy in geriatric HIV patients: the GEPO cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2879-2886.	3.0	30
131	Practical Review of Recognition and Management of Obesity and Lipohypertrophy in Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2017, 64, 1422-1429.	5.8	53
132	Geriatric-HIV Medicine Is Born. <i>Clinical Infectious Diseases</i> , 2017, 65, 507-509.	5.8	28
133	Atherosclerosis in frailty: Not frailty in atherosclerosis. <i>Atherosclerosis</i> , 2017, 266, 226-227.	0.8	3
134	Pregnant with HIV before age 25: data from a large national study in Italy, 2001-2016. <i>Epidemiology and Infection</i> , 2017, 145, 2360-2365.	2.1	2
135	Correlates of frailty phenotype and frailty index and their associations with clinical outcomes. <i>HIV Medicine</i> , 2017, 18, 764-771.	2.2	44
136	Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 338-342.	2.1	9
137	Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. <i>Aids</i> , 2017, 31, 2503-2514.	2.2	65
138	Late presentation increases risk and costs of non-infectious comorbidities in people with HIV: an Italian cost impact study. <i>AIDS Research and Therapy</i> , 2017, 14, 8.	1.7	31
139	Geriatric syndromes: How to treat. <i>Virulence</i> , 2017, 8, 577-585.	4.4	25
140	Pituitary growth hormone (GH) secretion is partially rescued in HIV-infected patients with GH deficiency (GHD) compared to hypopituitary patients. <i>Endocrine</i> , 2017, 55, 885-898.	2.3	5
141	Lower Frailty Is Associated with Successful Cognitive Aging Among Older Adults with HIV. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 157-163.	1.1	35
142	Multimorbidity and Burden of Disease. <i>Interdisciplinary Topics in Gerontology and Geriatrics</i> , 2017, 42, 59-73.	2.6	19
143	Impact of polypharmacy on antiretroviral prescription in people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 511-514.	3.0	21
144	Successful Pre- and Posttransplant Sofosbuvir-Based Anti-Hepatitis C Virus Treatment in Persons Living With Human Immunodeficiency Virus Infection. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx065.	0.9	9

#	ARTICLE	IF	CITATIONS
145	Aging in HIV-Infected Subjects: A New Scenario and a New View. <i>BioMed Research International</i> , 2017, 2017, 1-9.	1.9	56
146	A frailty index predicts post-liver transplant morbidity and mortality in HIV-positive patients. <i>AIDS Research and Therapy</i> , 2017, 14, 37.	1.7	19
147	High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal Fluid. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx108.	0.9	17
148	Predictors of transitions in frailty severity and mortality among people aging with HIV. <i>PLoS ONE</i> , 2017, 12, e0185352.	2.5	33
149	Bone Biomarkers in HIV. <i>Biomarkers in Disease</i> , 2017, , 755-781.	0.1	0
150	The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients. <i>PLoS ONE</i> , 2016, 11, e0168265.	2.5	15
151	Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. <i>World Journal of Gastroenterology</i> , 2016, 22, 9674.	3.3	93
152	More than osteoporosis. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 343-350.	3.8	15
153	An Update on Heart Transplantation in Human Immunodeficiency Virus-Infected Patients. <i>American Journal of Transplantation</i> , 2016, 16, 21-28.	4.7	36
154	Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1319-1329.	3.7	13
155	Independent association of subclinical coronary artery disease and emphysema in HIV-infected patients. <i>HIV Medicine</i> , 2016, 17, 178-187.	2.2	12
156	Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 936-944.	2.8	537
157	Th1 and Th17 proinflammatory profile characterizes invariant natural killer T cells in virologically suppressed HIV+ patients with low CD4+/CD8+ ratio. <i>Aids</i> , 2016, 30, 2599-2610.	2.2	30
158	HCV-HIV coinfecting pregnant women: data from a multicentre study in Italy. <i>Infection</i> , 2016, 44, 235-242.	4.7	19
159	Prediction of hard cardiovascular events in HIV patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3515-3518.	3.0	20
160	Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy. <i>Digestive and Liver Disease</i> , 2016, 48, 1399-1401.	0.9	8
161	Pregnancy outcomes and cytomegalovirus DNAemia in HIV-infected pregnant women with CMV. <i>Clinical Microbiology and Infection</i> , 2016, 22, 818-820.	6.0	2
162	Kidney Transplantation in HIV-Infected Recipients: Therapeutic Strategy and Outcomes in Monocentric Experience. <i>Transplantation Proceedings</i> , 2016, 48, 333-336.	0.6	6

#	ARTICLE	IF	CITATIONS
163	Serum total estradiol, but not testosterone is associated with reduced bone mineral density (BMD) in HIV-infected men: a cross-sectional, observational study. <i>Osteoporosis International</i> , 2016, 27, 1103-1114.	3.1	25
164	Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1637-1642.	3.0	8
165	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. <i>Clinical Microbiology and Infection</i> , 2016, 22, 288.e1-288.e8.	6.0	33
166	Ageing and inflammation in patients with HIV infection. <i>Clinical and Experimental Immunology</i> , 2016, 187, 44-52.	2.6	214
167	The transition from co-morbidities to geriatric syndromes in HIV. <i>Germs</i> , 2016, 6, 79-81.	1.3	6
168	Emphysema Distribution and Diffusion Capacity Predict Emphysema Progression in Human Immunodeficiency Virus Infection. <i>PLoS ONE</i> , 2016, 11, e0167247.	2.5	10
169	Frailty in HIV. , 2016, , 67-88.		0
170	Bone Biomarkers in HIV. <i>Exposure and Health</i> , 2016, , 1-27.	4.9	0
171	HIV Associated Non-AIDS Conditions in Patients Aging with HIV. , 2016, , 19-52.		1
172	Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the ICONA foundation cohort. <i>HIV Medicine</i> , 2015, 16, 412-420.	2.2	4
173	Analysis of inflammasomes and antiviral sensing components reveals decreased expression of NLRX1 in HIV-positive patients assuming efficient antiretroviral therapy. <i>Aids</i> , 2015, 29, 1937-1941.	2.2	18
174	A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. <i>Aids</i> , 2015, 29, 1633-1641.	2.2	136
175	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 452-455.	2.1	1
176	Lung and Heart Diseases Are Better Predicted by Pack-Years than by Smoking Status or Duration of Smoking Cessation in HIV Patients. <i>PLoS ONE</i> , 2015, 10, e0143700.	2.5	10
177	Is "Option B+" Also Being Adopted in Pregnant Women in High-Income Countries? Temporal Trends From a National Study in Italy. <i>Clinical Infectious Diseases</i> , 2015, 60, 159-161.	5.8	3
178	Epicardial adipose tissue and coronary artery calcium predict incident myocardial infarction and death in HIV-infected patients. <i>Journal of Cardiovascular Computed Tomography</i> , 2015, 9, 553-558.	1.3	31
179	Recommendations for Evaluation and Management of Bone Disease in HIV. <i>Clinical Infectious Diseases</i> , 2015, 60, 1242-1251.	5.8	150
180	Full Viral Suppression, Low-Level Viremia, and Quantifiable Plasma HIV-RNA at the End of Pregnancy in HIV-Infected Women on Antiretroviral Treatment. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 673-678.	1.1	1

#	ARTICLE	IF	CITATIONS
181	Low testosterone is associated with poor health status in men with human immunodeficiency virus infection: a retrospective study. <i>Andrology</i> , 2015, 3, 298-308.	3.5	41
182	Aging with HIV vs. HIV Seroconversion at Older Age: A Diverse Population with Distinct Comorbidity Profiles. <i>PLoS ONE</i> , 2015, 10, e0118531.	2.5	81
183	Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk?. <i>World Journal of Cardiology</i> , 2015, 7, 633.	1.5	39
184	Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19806.	3.0	4
185	Predictors of emphysema progression in HIV-positive patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19660.	3.0	1
186	Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial. <i>International Journal of STD and AIDS</i> , 2014, 25, 207-212.	1.1	13
187	Rate, Predictors, and Consequences of Late Antenatal Booking in a National Cohort Study of Pregnant Women With HIV in Italy. <i>HIV Clinical Trials</i> , 2014, 15, 104-115.	2.0	11
188	Surrogate markers of visceral adipose tissue in treated HIV-infected patients: accuracy of waist circumference determination. <i>HIV Medicine</i> , 2014, 15, 98-107.	2.2	5
189	Male sexual dysfunction and HIV—a clinical perspective. <i>Nature Reviews Urology</i> , 2014, 11, 99-109.	3.8	42
190	Multimorbidity and functional status assessment. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 386-397.	3.8	35
191	Gender differences in GH response to GHRH+ARG in lipodystrophic patients with HIV: a key role for body fat distribution. <i>European Journal of Endocrinology</i> , 2014, 170, 685-696.	3.7	10
192	Clinical and epidemiological features of HIV/AIDS infection among migrants at first access to healthcare services as compared to Italian patients in Italy: a retrospective multicentre study, 2000–2010. <i>Infection</i> , 2014, 42, 859-867.	4.7	18
193	The natural history of HIV-associated lipodystrophy in the changing scenario of HIV infection. <i>HIV Medicine</i> , 2014, 15, 587-594.	2.2	26
194	Intact parathyroid hormone levels are associated with increased carotid intima media thickness in HIV infected patients. <i>Atherosclerosis</i> , 2014, 237, 618-622.	0.8	6
195	Urolithiasis associated with atazanavir may mask a metabolic 'channelling' bias. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 284-285.	3.0	1
196	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 735-741.	3.0	16
197	Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1377-1384.	3.0	13
198	Frailty in People Aging With Human Immunodeficiency Virus (HIV) Infection. <i>Journal of Infectious Diseases</i> , 2014, 210, 1170-1179.	4.0	127

#	ARTICLE	IF	CITATIONS
199	Hypogonadism in the HIV-Infected Man. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 709-730.	3.2	77
200	Life Expectancy in the Immune Recovery Era. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 65, 175-181.	2.1	23
201	Relationship Between Health-Related Quality of Life Measures and High HIV Viral Load in HIV-Infected Triple-Class-Experienced Patients. <i>HIV Clinical Trials</i> , 2014, 15, 176-183.	2.0	18
202	The Burden of Image Based Emphysema and Bronchiolitis in HIV-Infected Individuals on Antiretroviral Therapy. <i>PLoS ONE</i> , 2014, 9, e109027.	2.5	27
203	Metabolic alterations in HIV-infected pregnant women: moving to metabolic tailoring of antiretroviral drugs. <i>AIDS Reviews</i> , 2014, 16, 14-22.	1.0	5
204	Morbidity in older HIV-infected patients: impact of long-term antiretroviral use. <i>AIDS Reviews</i> , 2014, 16, 75-89.	1.0	40
205	Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. <i>Clinical Infectious Diseases</i> , 2013, 57, 112-121.	5.8	56
206	Effects of pregnancy on endothelial function and cardiovascular disease risk in HIV-infected women. <i>Pregnancy Hypertension</i> , 2013, 3, 105-110.	1.4	5
207	HIV-Associated Lipodystrophy: Impact of Antiretroviral Therapy. <i>Drugs</i> , 2013, 73, 1431-1450.	10.9	47
208	Inverse Correlation Between Vascular Calcification and Bone Mineral Density in Human Immunodeficiency Virus-Infected Patients. <i>Calcified Tissue International</i> , 2013, 93, 413-418.	3.1	8
209	CD8 T-Cell Activation Is Associated With Lipodystrophy and Visceral Fat Accumulation in Antiretroviral Therapy-Treated Virologically Suppressed HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 64, 360-366.	2.1	19
210	Tesamorelin for the treatment of excess abdominal fat in HIV-infected individuals with lipodystrophy. <i>Clinical Investigation</i> , 2013, 3, 763-775.	0.0	1
211	Multicenter Italian Experience in Liver Transplantation for Hepatocellular Carcinoma in HIV-Infected Patients. <i>Oncologist</i> , 2013, 18, 592-599.	3.7	39
212	Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 193-199.	3.0	10
213	Body Mass Index and Weight Gain in Pregnant Women With HIV: A National Study in Italy. <i>Clinical Infectious Diseases</i> , 2013, 56, 1190-1193.	5.8	0
214	Randomized Trial to Evaluate Cardiometabolic and Endothelial Function in Patients with Plasma HIV-1 RNA Suppression Switching to Darunavir/Ritonavir with or without Nucleoside Analogues. <i>HIV Clinical Trials</i> , 2013, 14, 140-148.	2.0	14
215	Pregnancy Outcomes in HIV-Infected Women of Advanced Maternal Age. <i>HIV Clinical Trials</i> , 2013, 14, 110-119.	2.0	4
216	Cost of noninfectious comorbidities in patients with HIV. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 481.	1.9	46

#	ARTICLE	IF	CITATIONS
217	Combined Use of Waist and Hip Circumference to Identify Abdominally Obese HIV-Infected Patients at Increased Health Risk. <i>PLoS ONE</i> , 2013, 8, e62538.	2.5	7
218	Characterization of Specific Immune Responses to Different <i>Aspergillus</i> Antigens during the Course of Invasive <i>Aspergillosis</i> in Hematologic Patients. <i>PLoS ONE</i> , 2013, 8, e74326.	2.5	48
219	MR quantitative biomarkers of non-alcoholic fatty liver disease: technical evolutions and future trends. <i>Quantitative Imaging in Medicine and Surgery</i> , 2013, 3, 192-5.	2.0	28
220	Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors. <i>International Journal of STD and AIDS</i> , 2012, 23, 459-463.	1.1	10
221	Adverse Outcome Analyses of Observational Data: Assessing Cardiovascular Risk in HIV Disease. <i>Clinical Infectious Diseases</i> , 2012, 54, 408-413.	5.8	16
222	GH response to GHRH plus arginine is impaired in lipotrophic women with human immunodeficiency virus compared with controls. <i>European Journal of Endocrinology</i> , 2012, 166, 415-424.	3.7	14
223	Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-Naïve Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir. <i>HIV Clinical Trials</i> , 2012, 13, 245-255.	2.0	24
224	A Randomized, Pilot Trial to Evaluate Glomerular Filtration Rate by Creatinine or Cystatin C in Naive HIV-Infected Patients After Tenofovir/Emtricitabine in Combination With Atazanavir/Ritonavir or Efavirenz. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 18-24.	2.1	37
225	Long-Term Efficacy and Safety of Polyacrylamide Hydrogel Injection in the Treatment of Human Immunodeficiency Virus-Related Facial Lipoatrophy. <i>Plastic and Reconstructive Surgery</i> , 2012, 129, 101-109.	1.4	25
226	Magnetic Resonance for Quantitative Assessment of Liver Steatosis: A New Potential Tool to Monitor Antiretroviral-Drug-Related Toxicities. <i>Antiviral Therapy</i> , 2012, 17, 965-971.	1.0	11
227	Aseptic Osteonecrosis. <i>Transplantation</i> , 2012, 94, e20-e21.	1.0	0
228	Use of Specific Antiretroviral Regimens Among HIV-Infected Women in Italy at Time of Conception: 2001-2011. <i>AIDS Patient Care and STDs</i> , 2012, 26, 439-443.	2.5	7
229	Parallel increase of subclinical atherosclerosis and epicardial adipose tissue in patients with HIV. <i>American Heart Journal</i> , 2012, 163, 1024-1030.	2.7	27
230	The Aging Skeleton: Differences Between HIV-Infected Patients and the Uninfected Aging Population. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2012, 10, 257-265.	0.8	3
231	T Cell Activation but Not Polyfunctionality after Primary HIV Infection Predicts Control of Viral Load and Length of the Time without Therapy. <i>PLoS ONE</i> , 2012, 7, e50728.	2.5	19
232	Ectopic Fat is Linked to Prior Cardiovascular Events in Men With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 494-497.	2.1	42
233	Progression of coronary artery calcium in men affected by human immunodeficiency virus infection. <i>International Journal of Cardiovascular Imaging</i> , 2012, 28, 935-941.	1.5	26
234	Erectile Dysfunction is Not a Mirror of Endothelial Dysfunction in HIV-Infected Patients. <i>Journal of Sexual Medicine</i> , 2012, 9, 1114-1121.	0.6	18

#	ARTICLE	IF	CITATIONS
235	Erectile Dysfunction Is More Common in Young to Middle-Aged HIV-Infected Men than in HIV-Uninfected Men. <i>Journal of Sexual Medicine</i> , 2012, 9, 1923-1930.	0.6	41
236	High-density Hyaluronic Acid for the Treatment of HIV-related Facial Lipoatrophy. <i>Aesthetic Plastic Surgery</i> , 2012, 36, 180-185.	0.9	13
237	Evolving approaches and resources for clinical practice in the management of HIV infection in the HAART era. <i>Germes</i> , 2012, 1, 6-8.	1.3	10
238	Comparison of Three Different Methods for Correction of HIV-Associated Facial Lipodystrophy. , 2012, , 723-728.		0
239	Anthropometry in the Assessment of HIV-Related Lipodystrophy. , 2012, , 2459-2471.		0
240	Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General Population. <i>Clinical Infectious Diseases</i> , 2011, 53, 1120-1126.	5.8	1,044
241	<i>Fusarium verticillioides</i> fungemia in a liver transplantation patient: successful treatment with voriconazole. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 438-441.	1.8	20
242	Morphological and Metabolic Components of Lipodystrophy in Various Nevirapine-Based Highly Active Antiretroviral Therapy (HAART) Regimens. <i>Clinical Drug Investigation</i> , 2011, 31, 759-767.	2.2	2
243	Knowledge, attitudes and practice (KAP) regarding newborn feeding modalities in HIV-infected and HIV-uninfected pregnant women in sub-Saharan Africa: a multicentre study. <i>International Health</i> , 2011, 3, 56-65.	2.0	5
244	Premature Decline of Serum Total Testosterone in HIV-Infected Men in the HAART-Era. <i>PLoS ONE</i> , 2011, 6, e28512.	2.5	116
245	Surgical correction of HIV-associated facial lipoatrophy. <i>Aids</i> , 2011, 25, 1-12.	2.2	28
246	Glucose Plasma Levels and Pregnancy Outcomes in Women with HIV. <i>HIV Clinical Trials</i> , 2011, 12, 299-312.	2.0	1
247	Epicardial adipose tissue in HIV-infected patients. <i>Aids</i> , 2011, 25, 2190.	2.2	1
248	University of Modena Experience in HIV-Positive Patients Undergoing Liver Transplantation. <i>Transplantation Proceedings</i> , 2011, 43, 1114-1118.	0.6	17
249	Human Immunodeficiency Virus Is the Major Determinant of Steatosis and Hepatitis C Virus of Insulin Resistance in Virus-associated Fatty Liver Disease. <i>Archives of Medical Research</i> , 2011, 42, 690-697.	3.3	22
250	Common occurrence of anaemia at the end of pregnancy following exposure to zidovudine-free regimens. <i>Journal of Infection</i> , 2011, 63, 144-150.	3.3	3
251	Rubella Susceptibility Profile in Pregnant Women with HIV. <i>Clinical Infectious Diseases</i> , 2011, 52, 960-962.	5.8	5
252	Hepatocellular Carcinoma in HIV-Infected Patients: Check Early, Treat Hard. <i>Oncologist</i> , 2011, 16, 1258-1269.	3.7	92

#	ARTICLE	IF	CITATIONS
253	Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection. <i>Aids</i> , 2011, 25, 525-529.	2.2	32
254	Epicardial adipose tissue is an independent marker of cardiovascular risk in HIV-infected patients. <i>Aids</i> , 2011, 25, 1199-1205.	2.2	52
255	Human immunodeficiency virus infection is associated with accelerated atherosclerosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1857-1860.	3.0	16
256	Hypertriglyceridemia and Waist Circumference Predict Cardiovascular Risk among HIV Patients: A Cross-Sectional Study. <i>PLoS ONE</i> , 2011, 6, e25032.	2.5	24
257	Once-a-Day (QD) vs Twice-Daily (BID) Nevirapine as Simplification in PI-treated Patients After 2 mos. of BID Induction. <i>Current HIV Research</i> , 2011, 9, 166-173.	0.5	1
258	First Report on a Series of HIV Patients Undergoing Rapamycin Monotherapy After Liver Transplantation. <i>Transplantation</i> , 2010, 89, 733-738.	1.0	58
259	Upregulation of nuclear-encoded mitochondrial LON protease in HAART-treated HIV-positive patients with lipodystrophy: implications for the pathogenesis of the disease. <i>Aids</i> , 2010, 24, 841-850.	2.2	35
260	Declining HCV seroprevalence in pregnant women with HIV. <i>Epidemiology and Infection</i> , 2010, 138, 1317-1321.	2.1	6
261	Nonalcoholic Fatty Liver Disease in HIV-Infected Persons: Epidemiology and the Role of Nucleoside Reverse Transcriptase Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 278.	2.1	6
262	Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. <i>Aids</i> , 2010, 24, 885-890.	2.2	46
263	From lipodystrophy to cardiovascular disease: new insight into the management of HIV infection. <i>Clinical Lipidology</i> , 2010, 5, 583-593.	0.4	0
264	Rapamycin and HIV Replication in Liver Transplant Recipients. <i>Transplantation</i> , 2010, 90, 1040.	1.0	0
265	Brucellosis in a patient with end-stage liver disease undergoing liver transplantation: Successful treatment with tigecycline. <i>Liver Transplantation</i> , 2010, 16, 1215-1216.	2.4	13
266	HIV and the body: a review of multidisciplinary management. <i>HIV Medicine</i> , 2010, 11, 1-8.	2.2	26
267	Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. <i>Atherosclerosis</i> , 2010, 208, 222-227.	0.8	61
268	Facial Fat Hypertrophy in Patients Who Receive Autologous Fat Tissue Transfer. , 2010, , 427-431.		1
269	Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection. <i>AIDS Reviews</i> , 2010, 12, 3-14.	1.0	29
270	Heterologous Fat Transplantation for the Treatment of HIV-Related Facial Lipoatrophy. <i>Annals of Internal Medicine</i> , 2009, 150, 61.	3.9	3

#	ARTICLE	IF	CITATIONS
271	Plasma Lipid Profile in Pregnant Women with HIV Receiving Nevirapine. <i>AIDS Patient Care and STDs</i> , 2009, 23, 147-152.	2.5	2
272	Antiretroviral Treatment in Pregnancy: A Six-Year Perspective on Recent Trends in Prescription Patterns, Viral Load Suppression, and Pregnancy Outcomes. <i>AIDS Patient Care and STDs</i> , 2009, 23, 513-520.	2.5	39
273	Rate and Predictors of Self-Chosen Drug Discontinuations in Highly Active Antiretroviral Therapy-Treated HIV-Positive Individuals. <i>AIDS Patient Care and STDs</i> , 2009, 23, 35-39.	2.5	8
274	Coronary Aging in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 1756-1762.	5.8	106
275	Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men. <i>Aids</i> , 2009, 23, 2191-2198.	2.2	33
276	Evolving perspectives on HIV-associated lipodystrophy syndrome: moving from lipodystrophy to non-infectious HIV co-morbidities. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 437-440.	3.0	13
277	Metabolic disorders induced by highly active antiretroviral therapy and their relationship with vascular remodeling of the brachial artery in a population of HIV-infected patients. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 927-933.	3.4	7
278	Differential Dose Adjustments of Immunosuppressants after Resuming Boosted versus Unboosted HIV-Protease Inhibitors Postliver Transplant. <i>American Journal of Transplantation</i> , 2009, 9, 2429-2434.	4.7	9
279	Efficacy and Safety of Atazanavir in Patients with End-Stage Liver Disease. <i>Infection</i> , 2009, 37, 250-255.	4.7	12
280	Hyperhomocysteinaemia in HIV-Infected patients: determinants of variability and correlations with predictors of cardiovascular disease. <i>HIV Medicine</i> , 2009, 10, 28-34.	2.2	12
281	The Role of the Framingham Risk Score to Predict the Presence of Subclinical Coronary Atherosclerosis in Patients with HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 303-304.	2.1	7
282	Detectable HIV Viral Load Is Associated With Metabolic Syndrome. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 459-464.	2.1	27
283	Body image is a major determinant of sexual dysfunction in stable HIV-infected women. <i>Antiviral Therapy</i> , 2009, 14, 85-92.	1.0	35
284	European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV-infected patients. <i>HIV Medicine</i> , 2008, 9, 72-81.	2.2	189
285	Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: a cross-sectional study. <i>HIV Medicine</i> , 2008, 9, 151-159.	2.2	3
286	What Is the Biopsychosocial Role of Human Immunodeficiency Virus Positivity in Patients With End-Stage Liver Disease Who Undergo Orthotopic Liver Transplantation?. <i>Transplantation Proceedings</i> , 2008, 40, 1910-1912.	0.6	3
287	Human Immunodeficiency Virus and Liver Transplantation: Our Point of View. <i>Transplantation Proceedings</i> , 2008, 40, 1965-1971.	0.6	31
288	Hepatocellular carcinoma in HIV patients treated by liver transplantation. <i>European Journal of Surgical Oncology</i> , 2008, 34, 422-427.	1.0	51

#	ARTICLE	IF	CITATIONS
289	Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 374-379.	3.0	15
290	Reply to Remtulla and Decker. <i>Clinical Infectious Diseases</i> , 2008, 47, 1234-1234.	5.8	0
291	A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1356-1364.	3.0	13
292	Nonalcoholic Fatty Liver Disease in HIV-Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors. <i>Clinical Infectious Diseases</i> , 2008, 47, 250-257.	5.8	208
293	Mitochondrial DNA Haplogroups and Highly Active Antiretroviral Therapy-Related Lipodystrophy. <i>Clinical Infectious Diseases</i> , 2008, 47, 962-968.	5.8	26
294	HHV-6A in Syncytial Giant-Cell Hepatitis. <i>New England Journal of Medicine</i> , 2008, 359, 593-602.	27.0	99
295	Severity of Lipodystrophy Is Associated with Decreased Health-Related Quality of Life. <i>AIDS Patient Care and STDs</i> , 2008, 22, 577-585.	2.5	41
296	Factors Influencing Gestational Age-Adjusted Birthweight in a National Series of 600 Newborns from Mothers with HIV. <i>HIV Clinical Trials</i> , 2008, 9, 287-297.	2.0	11
297	Combined liver-kidney transplantation in an HIV-HCV-coinfected patient with haemophilia. <i>Aids</i> , 2008, 22, 2047-2049.	2.2	5
298	Polyacrylamide Hydrogel Injection in the Management of Human Immunodeficiency Virus-Related Facial Lipoatrophy: A 2-Year Clinical Experience. <i>Plastic and Reconstructive Surgery</i> , 2008, 121, 644-653.	1.4	67
299	Lipodystrophy and quality of life of HIV-infected persons. <i>AIDS Reviews</i> , 2008, 10, 152-61.	1.0	31
300	Hypopituitarism and HIV-infection: a new comorbidity in the HAART era?. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 33-8.	3.3	13
301	Long-Term Psychometric Outcomes of Facial Lipoatrophy Therapy: Forty-Eight-Week Observational, Nonrandomized Study. <i>AIDS Patient Care and STDs</i> , 2007, 21, 833-842.	2.5	25
302	Prevalence of and Risk Factors for Pubic Lipoma Development in HIV-Infected Persons. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 72-76.	2.1	14
303	Gram-Positive Bloodstream Infections in Liver Transplant Recipients: Incidence, Risk Factors, and Impact on Survival. <i>Transplantation Proceedings</i> , 2007, 39, 1947-1949.	0.6	27
304	Pregnancy outcomes and antiretroviral treatment in a national cohort of pregnant women with HIV: overall rates and differences according to nationality. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2007, 114, 896-900.	2.3	6
305	Mitochondrial complex III deficiency in a case of HCV related noninflammatory myopathy. <i>Journal of Neurology</i> , 2007, 254, 1450-1452.	3.6	3
306	First Italian Consensus Statement on Diagnosis, Prevention and Treatment of Cardiovascular Complications in HIV-infected Patients in the HAART Era (2006). <i>Infection</i> , 2007, 35, 134-142.	4.7	14

#	ARTICLE	IF	CITATIONS
307	Treatment with Protease Inhibitors and Coinfection with Hepatitis C Virus Are Independent Predictors of Preterm Delivery in HIV-Infected Pregnant Women. <i>Journal of Infectious Diseases</i> , 2007, 195, 913-914.	4.0	56
308	Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy. <i>Antiviral Therapy</i> , 2007, 12, 1059-65.	1.0	15
309	Sexual Dysfunction in HIV-Infected Men: Role of Antiretroviral Therapy, Hypogonadism and Lipodystrophy. <i>Antiviral Therapy</i> , 2007, 12, 1059-1066.	1.0	54
310	Fatal cytomegalovirus necrotising enteritis in a small bowel transplantation adult recipient with low pp65 antigenaemia levels. <i>Digestive and Liver Disease</i> , 2006, 38, 429-433.	0.9	4
311	Posttransplant Mycobacterium Tuberculosis Disease Following Liver Transplantation and the Need for Cautious Evaluation of Quantiferon TB GOLD Results in the Transplant Setting: A Case Report. <i>Transplantation Proceedings</i> , 2006, 38, 1083-1085.	0.6	24
312	Pharmacokinetic Interaction Between Amprenavir/Ritonavir and Fosamprenavir on Cyclosporine in Two Patients With Human Immunodeficiency Virus Infection Undergoing Orthotopic Liver Transplantation. <i>Transplantation Proceedings</i> , 2006, 38, 1138-1140.	0.6	19
313	Diagnosis of HIV infection in pregnancy: data from a national cohort of pregnant women with HIV in Italy. <i>Epidemiology and Infection</i> , 2006, 134, 1120-1127.	2.1	41
314	Multidisciplinary Approach to the Treatment of Metabolic and Morphologic Alterations of HIV-Related Lipodystrophy. <i>HIV Clinical Trials</i> , 2006, 7, 97-106.	2.0	45
315	Cardiovascular complications in HIV-infected individuals. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 507-513.	3.8	4
316	Lipodystrophy is an independent predictor of hypertriglyceridemia during pregnancy in HIV-infected women. <i>Aids</i> , 2006, 20, 944-947.	2.2	2
317	KSHV/HHV-8 Infection of Tubular Epithelial Cells in Transplantation Kidney. <i>Transplantation</i> , 2006, 82, 851-852.	1.0	7
318	Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. <i>Clinical Microbiology and Infection</i> , 2006, 12, 75-80.	6.0	81
319	Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 309-315.	2.4	57
320	Quality of Life and Body Image in the Assessment of Psychological Impact of Lipodystrophy: Validation of the Italian Version of Assessment of Body Change and Distress Questionnaire. <i>Quality of Life Research</i> , 2006, 15, 173-178.	3.1	46
321	Lipid Profile During Pregnancy in HIV-Infected Women. <i>HIV Clinical Trials</i> , 2006, 7, 184-193.	2.0	12
322	Comparison of a Rule-Based Algorithm with a Phenotype-Based Algorithm for the Interpretation of HIV Genotypes in Guiding Salvage Regimens in HIV-Infected Patients by a Randomized Clinical Trial: The Mutations and Salvage Study. <i>Clinical Infectious Diseases</i> , 2006, 42, 1470-1480.	5.8	11
323	Antiretroviral Therapy at Conception in Pregnant Women with HIV in Italy: Wide Range of Variability and Frequent Exposure to Contraindicated Drugs. <i>Antiviral Therapy</i> , 2006, 11, 941-946.	1.0	15
324	Outcome, Incidence, and Timing of Infectious Complications in Small Bowel and Multivisceral Organ Transplantation Patients. <i>Transplantation</i> , 2005, 80, 1742-1748.	1.0	84

#	ARTICLE	IF	CITATIONS
325	Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study. <i>Aids</i> , 2005, 19, 1627-1633.	2.2	56
326	Herpes simplex virus pneumonia during standard induction chemotherapy for acute leukemia: case report and review of literature. <i>Leukemia</i> , 2005, 19, 2019-2021.	7.2	16
327	A rare case of localized mucosal leishmaniasis due to <i>Leishmania infantum</i> in an immunocompetent Italian host. <i>European Journal of Epidemiology</i> , 2005, 20, 559-561.	5.7	20
328	Facial Lipohypertrophy in HIV-Infected Subjects Who Underwent Autologous Fat Tissue Transplantation. <i>Clinical Infectious Diseases</i> , 2005, 40, e13-e15.	5.8	52
329	Role of Therapeutic Drug Monitoring in a Patient With Human Immunodeficiency Virus Infection and End-Stage Liver Disease Undergoing Orthotopic Liver Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 2609-2610.	0.6	12
330	Rituximab as Treatment of Posttransplant Lymphoproliferative Disorder in Patients Who Underwent Small Bowel/Multivisceral Transplantation: Report of Three Cases. <i>Transplantation Proceedings</i> , 2005, 37, 2634-2635.	0.6	12
331	Liver resection of metastasis by colorectal cancer in a HIV patient. <i>Digestive and Liver Disease</i> , 2005, 38, 149-50.	0.9	0
332	Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study. <i>Antiviral Therapy</i> , 2005, 10, 753-9.	1.0	10
333	Comparison of Three Different Interventions for the Correction of HIV-Associated Facial Lipoatrophy: A Prospective Study. <i>Antiviral Therapy</i> , 2005, 10, 753-759.	1.0	58
334	Tolosa-Hunt Syndrome Due to Actinomycosis of the Cavernous Sinus: The Infectious Hypothesis Revisited. <i>Headache</i> , 2004, 44, 806-811.	3.9	30
335	Prevalence, Associated Factors, and Prognostic Determinants of AIDS-Related Toxoplasmic Encephalitis in the Era of Advanced Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2004, 39, 1681-1691.	5.8	131
336	Outcome, incidence, and timing of infections in small bowel/multivisceral transplantation. <i>Transplantation Proceedings</i> , 2004, 36, 383-385.	0.6	22
337	Alendronate Reduces Bone Resorption in HIV-Associated Osteopenia/Osteoporosis. <i>HIV Clinical Trials</i> , 2004, 5, 269-277.	2.0	74
338	Clinical Epidemiology and Survival of Progressive Multifocal Leukoencephalopathy in the Era of Highly Active Antiretroviral Therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA). <i>Journal of NeuroVirology</i> , 2003, 9, 47-53.	2.1	157
339	Human Herpesvirus 8-Associated Diseases in Solid-Organ Transplantation: Importance of Viral Transmission from the Donor. <i>Clinical Infectious Diseases</i> , 2003, 37, 606-607.	5.8	26
340	Morphologic Alterations in HIV-Infected People with Lipodystrophy Are Associated with Good Adherence to HAART. <i>HIV Clinical Trials</i> , 2003, 4, 99-106.	2.0	38
341	Clinical Epidemiology and Survival of Progressive Multifocal Leukoencephalopathy in the Era of Highly Active Antiretroviral Therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA). <i>Journal of NeuroVirology</i> , 2003, 9, 47-53.	2.1	12
342	Case of fatal encephalitis by HHV-6 variant A. <i>Journal of Medical Virology</i> , 2001, 65, 133-137.	5.0	33

#	ARTICLE	IF	CITATIONS
343	Alendronate Treatment for Osteoporosis in Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2001, 33, 414-415.	5.8	11
344	Role of PCR in Diagnosis and Prognosis of Visceral Leishmaniasis in Patients Coinfected with Human Immunodeficiency Virus Type 1. <i>Journal of Clinical Microbiology</i> , 2001, 39, 357-361.	3.9	75
345	Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy. <i>Aids</i> , 2001, 15, 137-138.	2.2	61
346	Lack of selective V β 2 deletion in CD4+ or CD8+ T lymphocytes and functional integrity of T-cell repertoire during acute HIV syndrome. <i>Aids</i> , 1995, 9, 547-554.	2.2	23
347	Non-typhoid Salmonella Subdural Empyema in a Patient with AIDS. <i>Scandinavian Journal of Infectious Diseases</i> , 1995, 27, 173-174.	1.5	3
348	Gastric localization of <i>Leishmania</i> in a patient with acquired immunodeficiency syndrome. <i>Apmis</i> , 1995, 103, 25-28.	2.0	8
349	Massive Activation of Immune Cells with an Intact T Cell Repertoire in Acute Human Immunodeficiency Virus Syndrome. <i>Journal of Infectious Diseases</i> , 1995, 172, 105-112.	4.0	72
350	Early Abnormalities of the Antibody Response against Mycobacterium tuberculosis in Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 1993, 168, 1409-1414.	4.0	16
351	Which criteria should we use to end isolation in hemodialysis patients with COVID-19?. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	2.9	3